+8.8%
ENPH vs GSK
+14.9%
-6.2%
-65.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.7% | +5.0% | -1.3% | +1.3% |
| 7D | +26.3% | +4.9% | +21.3% | +23.2% |
| 30D | -5.7% | +9.9% | -15.6% | -9.1% |
| 3M | -24.5% | +0.2% | -24.6% | -24.0% |
| 6M | -3.0% | +2.3% | -5.4% | -6.5% |
| YTD | -1.6% | +7.1% | -8.6% | -8.7% |
| 1Y | +8.8% | +13.1% | -4.4% | -2.6% |
| All | +8.8% | +14.9% | -6.2% | -2.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling